Missionirnewsbreaks Annovis Bio Inc. (NYSE: ANVS) Regains NYSE Listing Compliance

(MENAFN- Investor Brand Network) Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for Alzheimer's disease and Parkinson's disease, announced it has regained compliance with New York Stock Exchange continued listing standards after implementing corrective measures to restore its market capitalization and stockholders' equity above required thresholds, allowing its common stock to continue trading on the NYSE under the ticker symbol ANVS.

To view the full press release, visit

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit and follow us on LinkedIn, YouTube, and X.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company's newsroom at

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: imer, Texas

512.354.7000 Office
href="/cdn-cgi/l/email-protection#dd98b9b4a9b2af9d90b4aeaeb4b2b3948ff3beb2b0" target="_blank" rel="noreferrer noopener">[email protected]

MissionIR is powered by IBN

MENAFN26052026000224011066ID1111170405